AOD-9604 and Retatrutide are both Metabolic peptides, but they're studied for different things. In short, AOD-9604 is a growth-hormone fragment studied for fat metabolism, while Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
AOD-9604 vs Retatrutide at a glance
| AOD-9604 | Retatrutide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | A growth-hormone fragment studied for fat metabolism. | An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. |
| Researched for | Fat metabolism, Body composition, Cartilage/joint studies | Weight management, Blood sugar regulation, Metabolic health |
| Research status | Human trials for obesity did not meet primary endpoints; further research ongoing. | Phase III clinical trials — investigational, not yet approved. |
| Typically stacked with | — | — |
| Key consideration | Weight-loss efficacy was not established in clinical trials. Not an approved therapy. | Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision. |
How does AOD-9604 work?
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (residues 176-191). It was designed to stimulate fat metabolism (lipolysis) without the growth-promoting or blood-sugar effects of full-length growth hormone.
How does Retatrutide work?
Retatrutide is an investigational "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite and glycemic effects of GIP/GLP-1, and early trials have shown substantial weight reduction.
AOD-9604 vs Retatrutide: how to choose
Choosing between AOD-9604 and Retatrutide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. AOD-9604 is most associated with Fat metabolism and Body composition, while Retatrutide leans toward Weight management and Blood sugar regulation. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. AOD-9604 is a growth-hormone fragment studied for fat metabolism; Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist studied for weight loss. They're most researched for Fat metabolism, Body composition (AOD-9604) and Weight management, Blood sugar regulation (Retatrutide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
AOD-9604: Human trials for obesity did not meet primary endpoints; further research ongoing. Retatrutide: Phase III clinical trials — investigational, not yet approved.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.